Price (delayed)
$2.51
Market cap
$123.11M
P/E Ratio
13.21
Dividend/share
N/A
EPS
$0.19
Enterprise value
$154.55M
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights
There are no recent dividends present for PBYI.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.